AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
253.91B
Market cap253.91B
Price-Earnings ratio
23.77
Price-Earnings ratio23.77
Dividend yield
1.68%
Dividend yield1.68%
Average volume
3.15M
Average volume3.15M
High today
$164.53
High today$164.53
Low today
$162.14
Low today$162.14
Open price
$164.05
Open price$164.05
Volume
2.51M
Volume2.51M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$145.79
52 Week low$145.79

Stock Snapshot

With a market cap of 253.91B, AstraZeneca(AZN) trades at $163.72. The stock has a price-to-earnings ratio of 23.77 and currently yields dividends of 1.68%.

On 2026-09-14, AstraZeneca(AZN) stock moved within a range of $162.14 to $164.53. With shares now at $163.72, the stock is trading +1.0% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 2.51M, compared to an average daily volume of 3.15M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

AZN News

TipRanks 3h
AstraZeneca Deepens Real-World Safety Check on Eplontersen for Amyloidosis

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new safety study tracks long-term use of eplontersen in patients wi...

Benzinga 7h
Why Is AstraZeneca Stock Trading Higher Today?

AstraZeneca Plc (NYSE:AZN) reported updated clinical outcomes across its oncology portfolio, demonstrating sustained long-term survival advantages in lung cance...

Why Is AstraZeneca Stock Trading Higher Today?
TipRanks 7h
AstraZeneca: Buy Rating Reaffirmed on Robust Pipeline and Attractive Valuation; Price Target Unchanged at $16,500

Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca and keeping the price target at p16,500.00. Sachin Jain has given hi...

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More AZN News

TipRanks 7h
Olema Oncology price target lowered to $30 from $48 at Stifel

Stifel lowered the firm’s price target on Olema Oncology (OLMA) to $30 from $48 and keeps a Buy rating on the shares after AstraZeneca (AZN) announced on Friday...

TipRanks 10h
AstraZeneca reports results from DESTINY-Lung04 trial

Results from the DESTINY-Lung04 Phase III trial showed AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu demonstrated a statistically significant and clinically me...

Bloomberg 12h
Astra Breast Cancer Pill Miss May Trim Billions From Sales - Bloomberg.com

...

Astra Breast Cancer Pill Miss May Trim Billions From Sales - Bloomberg.com
Nasdaq 13h
AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective

(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the SERENA-4 Phase III trial of Etcamah or camizestrant in combination with palbociclib did not meet t...

AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective
The Wall Street Journal 14h
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

AstraZeneca continues to study the pill in other trials, both as standalone therapy and in combination with other drugs. Rachel Wisniewski / Reuters AstraZenec...

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
Nasdaq 1d
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears

Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Cong...

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears
Investor's Business Daily 3d
AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer

Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent? 8/27/2026 Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease t...

AstraZeneca Stock Trips On Unexpected Failure In Breast Cancer

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.